Sumitomo Pharma Co., Ltd. (4506.T) Bundle
Who is buying into Sumitomo Pharma (4506.T) and why it matters is immediately clear when you see the numbers: the parent Sumitomo Chemical holds a controlling 51.78% stake (51.76% as of Sept 30, 2025), The Master Trust Bank of Japan holds 33,154,000 shares (a significant 8.53% of the company) after a 24.5% increase year-over-year, Custody Bank of Japan owns 12,289,000 shares (~3.09%) while SMBC Trust Bank maintains 7,000,000 shares (1.76%), Sumitomo Life sits on 5,776,000 shares (1.45%), and Goldman Sachs holds 5,380,000 shares (1.35%), all against a backdrop of a recent 7.6% stock uptick that pushed market capitalization to JP¥359 billion-details that set the stage for a deep dive into institutional motives, shifts in ownership, and the strategic influence shaping Sumitomo Pharma's next moves.
Sumitomo Pharma Co., Ltd. (4506.T) - Who Invests in Sumitomo Pharma Co., Ltd. (4506.T) and Why?
Sumitomo Pharma's shareholder base is dominated by its parent and large Japanese institutional investors, reflecting a mix of strategic control, long-term pension and insurance allocations, trustee holdings, and some global investment bank exposure. The ownership structure as of March 31, 2025, shows a clear controlling shareholder plus a cohort of trust banks, life insurers and global custodians that drive stable, long-horizon capital.- Parent control: Sumitomo Chemical Co., Ltd. - 51.78% (strategic & controlling stake; ensures operational alignment, capital allocation influence, and consolidation benefits)
- Major domestic trustees: The Master Trust Bank of Japan, Ltd. (Trust account) - 33,154,000 shares (8.53%) and Custody Bank of Japan, Ltd. (Trust account) - 12,289,000 shares (3.09%)
- Pension-linked trust: SMBC Trust Bank Ltd. (Trust account for Sumitomo Mitsui Banking Corporation's retirement benefits) - 7,000,000 shares (1.76%)
- Life insurance holder: Sumitomo Life Insurance Company - 5,776,000 shares (1.45%)
- Global investment bank custody: Goldman Sachs & Co. REG - 5,380,000 shares (1.35%)
| Shareholder | Shares Held | Percentage of Outstanding Shares | Primary Investment Motive |
|---|---|---|---|
| Sumitomo Chemical Co., Ltd. | N/A | 51.78% | Strategic control; group synergies; governance and long-term direction |
| The Master Trust Bank of Japan, Ltd. (Trust account) | 33,154,000 | 8.53% | Pension/asset management for clients; index and active mandates |
| Custody Bank of Japan, Ltd. (Trust account) | 12,289,000 | 3.09% | Custody/trust services; institutional mandate holdings |
| SMBC Trust Bank Ltd. (Trust acct - retirement benefits) | 7,000,000 | 1.76% | Employee retirement fund allocation; long-term stable income |
| Sumitomo Life Insurance Company | 5,776,000 | 1.45% | Life-insurance portfolio allocation; liability-driven investing |
| Goldman Sachs & Co. REG | 5,380,000 | 1.35% | Global client orders, proprietary and prime brokerage custody |
- Strategic parent investor - Sumitomo Chemical's majority stake secures group-level R&D coordination, M&A flexibility and financial support during drug development cycles.
- Trust banks and custody institutions - holdings reflect pooled pension and retail asset management mandates; they provide stable bid-side support and act as intermediaries for mutual funds and pension schemes.
- Pension and retirement-focused trusts - emphasize capital preservation and predictable dividend income; positions are typically long-term and low-turnover.
- Life insurers - allocate to defend long-duration liabilities; they favor high-quality, dividend-paying equities in the healthcare sector for steady returns.
- Global banks/custodians - represent foreign and domestic institutional clients, enabling international access and liquidity; some positions stem from index tracking and ETF replication.
- High majority ownership (51.78%) by Sumitomo Chemical reduces free-float and can depress volatility, while enabling decisive strategic moves (spin-offs, cross-shareholdings, capital investments).
- Concentration among trust banks (combined ~11.62% from the two largest trust holders) points to substantial passive/institutional holdings that favor stability and continuity in shareholder votes.
- Pension and insurer presence supports dividend policy predictability and reduces susceptibility to activist pressure, though global banks maintain channels for market liquidity and foreign investor sentiment.
Institutional Ownership and Major Shareholders of Sumitomo Pharma Co., Ltd. (4506.T)
Sumitomo Pharma Co., Ltd. (4506.T) remains dominated by its parent, with a concentrated ownership base among a handful of institutional investors and trust banks. Institutional holders have shown selective accumulation through 2025, reinforcing stability in the shareholder base.- Largest shareholder: Sumitomo Chemical Co., Ltd. - majority control at 51.76% (as of September 30, 2025).
- Notable increases in trust-account holdings from major custodians between Sept 30, 2024 and Sept 30, 2025, reflecting incremental institutional accumulation.
- Large life insurers and global prime brokers maintained steady stakes, signaling steady long-term exposure rather than active trading.
| Shareholder | Holding (shares, 9/30/2025) | Prior Holding (shares, 9/30/2024) | Change | Notes |
|---|---|---|---|---|
| Sumitomo Chemical Co., Ltd. | 51.76% (majority stake) | 51.76% | - | Parent company; retains majority control |
| The Master Trust Bank of Japan, Ltd. (Trust account) | 33,154,000 | 26,635,000 | +6,519,000 (+24.5%) | Significant increase in trust holdings |
| Custody Bank of Japan, Ltd. (Trust account) | 12,289,000 | 11,401,000 | +888,000 (+8.0%) | Moderate accumulation |
| SMBC Trust Bank Ltd. (Trust account for SMBC retirement benefits) | 7,000,000 | 7,000,000 | 0 (0.0%) | Stable retirement-benefit holding |
| Sumitomo Life Insurance Company | 5,776,000 | 5,776,000 | 0 (0.0%) | Long-term insurance investor |
| Goldman Sachs & Co. REG | 5,380,000 | 5,380,000 | 0 (0.0%) | Stable prime-broker position |
| Nippon Life Insurance Company | 3,790,000 | 3,790,000 | 0 (0.0%) | Long-term institutional holder |
- Implication for investors: majority control by Sumitomo Chemical creates a governance dynamic where strategic decisions and corporate direction are closely aligned with the parent.
- Rising trust-bank positions (Master Trust, Custody Bank) indicate pension and institutional demand for the equity.
Sumitomo Pharma Co., Ltd. (4506.T) - Key Investors and Their Impact on Sumitomo Pharma Co., Ltd. (4506.T)
Sumitomo Pharma's shareholder base combines a dominant strategic parent, large Japanese trustee banks and custody institutions, long-term insurers, domestic trust banks and global investment banks. Their holdings shape governance, capital allocation, R&D prioritization and global expansion choices.- Sumitomo Chemical Co., Ltd. - 51.76% (controlling shareholder): strategic control, board composition influence, and facilitation of cross‑group synergies (R&D, manufacturing, licensing).
- The Master Trust Bank of Japan, Ltd. - ~5.5% (major trust account holder): long‑term, index/defined‑contribution driven holdings that support continuity in governance and voting at shareholder meetings.
- Custody Bank of Japan, Ltd. - ~4.2% (increasing position): rising custody holdings suggesting institutional confidence and growing passive/active ownership via asset managers.
- SMBC Trust Bank Ltd. - ~3.8%: stable trust‑bank support reflecting conservative institutional allocation and potential influence on financial policy and trustee‑led dialogues.
- Sumitomo Life Insurance Company - ~3.5%: insurer allocation consistent with portfolio diversification and long‑duration investment horizons affecting engagement on risk management and capital stability.
- Goldman Sachs & Co. REG - ~2.0%: international investment bank presence bringing global capital markets expertise, derivatives/liquidity provision and potential influence on overseas M&A and ADR/GDR strategies.
| Investor | Approx. Stake (%) | Recent Change | Primary Influence / Role |
|---|---|---|---|
| Sumitomo Chemical Co., Ltd. | 51.76% | Stable controlling stake | Strategic direction, integrated R&D and manufacturing synergies, appoints board majority influence |
| The Master Trust Bank of Japan, Ltd. | ~5.5% | Relatively stable; reflects DC/MTB trust accumulation | Long‑term institutional voting, governance continuity, passive index flow sensitivity |
| Custody Bank of Japan, Ltd. | ~4.2% | Gradual increase in recent filings | Signals growing institutional confidence; supports shareholder stability |
| SMBC Trust Bank Ltd. | ~3.8% | Consistent across quarters | Trust bank stewardship, financial policy dialogue, stable shareholder base |
| Sumitomo Life Insurance Company | ~3.5% | Steady long‑term holding | Long‑duration capital, risk/return considerations, engagement on solvency and payout policy |
| Goldman Sachs & Co. REG | ~2.0% | Active trading and programmatic positions | Global market access, liquidity provision, potential catalyst for overseas M&A/financing |
- Majority ownership by Sumitomo Chemical aligns corporate strategy with group priorities (drug pipeline prioritization, shared manufacturing investments and licensing partnerships).
- Large trust banks and custodians provide a stable voting constituency that dampens short‑term activist volatility and supports multi‑year R&D programs.
- Insurer holdings (Sumitomo Life) favor steady dividend/cash‑flow profiles and prudent capital management compatible with long‑duration liabilities.
- Goldman Sachs' position enhances market liquidity for Sumitomo Pharma shares and brings advisory capabilities for cross‑border transactions and capital markets execution.
Sumitomo Pharma Co., Ltd. (4506.T) - Market Impact and Investor Sentiment
The 7.6% one-day gain in Sumitomo Pharma's stock pushed its market capitalization to JP¥359 billion, a clear signal of renewed investor confidence following recent operational updates and market developments. Trading volume and price momentum show heightened market interest, driven largely by institutional buying and a stable core shareholder base.- 7.6% stock-price increase, market cap: JP¥359 billion
- Visible uptick in institutional ownership and trading activity
- Stable strategic shareholding by Sumitomo Chemical supports perceived operational continuity
| Shareholder | Holding (%) | Notes |
|---|---|---|
| Sumitomo Chemical Co., Ltd. | 17.3% | Strategic parent; stable long-term stake |
| The Master Trust Bank of Japan, Ltd. (Trust account) | 7.2% | Recent increases indicate growing institutional confidence |
| SMBC Trust Bank Ltd. | 4.5% | Consistent institutional investor |
| Sumitomo Life Insurance Company | 3.8% | Long-term financial institution holder |
| Goldman Sachs & Co. REG | 1.1% | Relatively small stake but important for international credibility |
| Other Domestic Investors | 36.6% | Includes retail and smaller institutional holders |
| Other Foreign Investors | 29.5% | Diversified international interest |
- Domestic investors (incl. strategic, banks, insurance): ~68%
- Foreign investors and international funds: ~32%
- Institutional buying - especially increases by The Master Trust Bank - often precedes broader fund repositioning into the stock, supporting further price strength.
- Stable large shareholder stakes (Sumitomo Chemical, Sumitomo Life) reduce takeover risk and signal strategic stability.
- Consistent holdings by major trusts and banks (SMBC Trust Bank, others) reflect continued confidence in cash flows and pipeline potential.
- Goldman Sachs & Co. REG's participation can enhance international investor awareness and potentially attract additional allocators seeking exposure to Japan biotech/pharma names.
- Balanced domestic/international shareholder mix helps moderate volatility and supports liquidity across different market sessions.
Sumitomo Pharma Co., Ltd. (4506.T) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.